Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 1:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 1,158 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Influenza vaccine Clear all
Recruiting Phase 3 Interventional

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

NCT05624450
View directory record Official record
Conditions
Viral Lung Infection and Acute Respiratory Failure
Interventions
Tozorakimab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
3,527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
75
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 15, 2026, 1:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Influenza Vaccination in Bone Marrow Transplantation

NCT00419224
View directory record Official record
Conditions
Influenza
Interventions
inactivated split-virus influenza vaccine
Biological
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 11, 2007 · Synced Oct 15, 2026, 1:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Do NSAIDS or Executing Exercise Decrease Local Erythema, Site Swelling & Pain After INoculation

NCT02807623
View directory record Official record
Conditions
Immune System and Related Disorders
Interventions
Ibuprofen, Compound Exercise of Push-ups, oral placebo
Drug · Behavioral
Lead sponsor
Womack Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Bethesda, Maryland • Fort Bragg, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 15, 2026, 1:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations

NCT03617523
View directory record Official record
Conditions
Influenza
Interventions
Fluzone Quadrivalent vaccine, 2018-2019 formulation, Flublok Quadrivalent vaccine, 2018-2019 formulation, Fluzone High-Dose vaccine, 2018-2019 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
3
States / cities
Bardstown, Kentucky • Metairie, Louisiana • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 15, 2026, 1:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Systems Biology of Trivalent Influenza Vaccine (TIV) in Young and Elderly

NCT01232868
View directory record Official record
Conditions
Influenza
Interventions
trivalent Influenza vaccine (TIV)
Biological
Lead sponsor
Emory University
Other
Eligibility
25 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 30, 2015 · Synced Oct 15, 2026, 1:57 PM EDT
Not listed No phase listed Observational

The DETECT(Digital Engagement & Tracking for Early Control, & Treatment) Study

NCT04336020
View directory record Official record
Conditions
Influenza, Virus
Interventions
Not listed
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
18 Years and older
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 15, 2026, 1:57 PM EDT
Completed Not applicable Interventional

Efficacy Study of School-located Influenza Vaccination Clinics to Increase Influenza Vaccination Rates in Monroe County, New York

NCT02227186
View directory record Official record
Conditions
Childhood Influenza Vaccination, School-located Influenza Vaccination
Interventions
School-located Influenza Vaccination Clinic
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
4 Years to 19 Years
Enrollment
20,461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Oct 15, 2026, 1:57 PM EDT
Completed No phase listed Observational

FLU A+B Nasal Swab Clinical Study

NCT00636662
View directory record Official record
Conditions
Influenza
Interventions
Non-invasive diagnostic testing
Other
Lead sponsor
Response Biomedical Corp.
Industry
Eligibility
Not listed
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
4
States / cities
Chicago, Illinois • St Louis, Missouri • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 15, 2026, 1:57 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults

NCT00985673
View directory record Official record
Conditions
Influenza
Interventions
GSK2340274A, GSK2340273A, Seasonal trivalent influenza vaccine (TIV), Saline placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years to 40 Years
Enrollment
611 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
4
States / cities
Stockbridge, Georgia • Raleigh, North Carolina • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 15, 2026, 1:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults

NCT03743688
View directory record Official record
Conditions
Influenza, Influenza, Human, Vaccine Reaction, Influenza A, Influenza Type B, Influenza A H1N1, Influenza A H3N2
Interventions
Influenza Vaccine Recipients
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Oct 15, 2026, 1:57 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Bone Marrow and Peripheral Blood Immune Responses Study

NCT05616546
View directory record Official record
Conditions
Influenza
Interventions
Influenza Vaccine
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 64 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 15, 2026, 1:57 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age

NCT07851246
View directory record Official record
Conditions
Influenza, Human
Interventions
mRNA Seasonal Flu vaccine, Comparator 1, Comparator 2
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
12
States / cities
Glendale, Arizona • Tucson, Arizona • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 15, 2026, 1:57 PM EDT
Completed Not applicable Interventional Results available

Patient Portal Flu Vaccine Reminders (RCT 6)

NCT06062264
View directory record Official record
Conditions
Influenza, Respiratory Tract Infections
Interventions
Portal-based Video Message, Portal-based Infographic Message
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
6 Months and older
Enrollment
22,233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Oct 15, 2026, 1:57 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above

NCT06361875
View directory record Official record
Conditions
Influenza Immunization, Healthy Volunteers
Interventions
Quadrivalent Influenza mRNA Vaccine MRT5421, Quadrivalent Influenza mRNA Vaccine MRT5424, Quadrivalent Influenza mRNA Vaccine MRT5429, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza High-Dose Vaccine, Quadrivalent Recombinant Influenza Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
908 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
11
States / cities
San Diego, California • Hialeah, Florida • Hollywood, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 15, 2026, 1:57 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults

NCT00192192
View directory record Official record
Conditions
Influenza
Interventions
CAIV-T
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000
U.S. locations
1
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Oct 15, 2026, 1:57 PM EDT
Completed No phase listed Observational

Respiratory Virus Hospitalization Study (FLU 003 Plus)

NCT01056185
View directory record Official record
Conditions
Influenza, Novel Respiratory Virus-1 Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV), Novel Respiratory Virus-2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2024
U.S. locations
18
States / cities
San Diego, California • Washington D.C., District of Columbia • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 15, 2026, 1:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

FLUAD® vs. Fluzone® High-Dose Study

NCT03183908
View directory record Official record
Conditions
Pain, Quality of Life, Injection Site Reaction, Side Effect of Drug, Adverse Drug Event
Interventions
FLUAD®, Fluzone® High-Dose
Biological
Lead sponsor
Duke University
Other
Eligibility
65 Years and older
Enrollment
757 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
4
States / cities
Atlanta, Georgia • Boston, Massachusetts • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 15, 2026, 1:57 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above

NCT05559476
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA investigational vaccine, FLU HD vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years and older
Enrollment
1,029 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
46
States / cities
Birmingham, Alabama • Tempe, Arizona • Canoga Park, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 15, 2026, 1:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus

NCT01405885
View directory record Official record
Conditions
Healthy
Interventions
INO-3605, INO-3609, INO-3401, INO-3605 AND INO-3609, INO-3510, Seasonal Influenza vaccine
Biological
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
3
States / cities
Miami, Florida • Overland Park, Kansas • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2014 · Synced Oct 15, 2026, 1:57 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A/Texas Flu Challenge

NCT06753474
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus influenza A H3N2 strain
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 15, 2026, 1:57 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Sanofi H1N1 + TIV - Adults and Elderly

NCT00943878
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine, Inactivated H1N1 Vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
805 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
5
States / cities
Decatur, Georgia • St Louis, Missouri • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 15, 2026, 1:57 PM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 15, 2026, 1:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)

NCT01831934
View directory record Official record
Conditions
MELAS Syndrome
Interventions
Fluzone®
Biological
Lead sponsor
Stanford University
Other
Eligibility
13 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 15, 2026, 1:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination

NCT00835926
View directory record Official record
Conditions
Influenza
Interventions
Influenza virus vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 15, 2026, 1:57 PM EDT